FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker in protoporphyria FDA indicated a need to see the results of the ongoing Phase 3 APOLLO study before making a decision Ongoing Phase 3 APOLLO study potential to serve as basis for traditional approval; topline data anticipated Q4 2026 WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIR

A simple shift in your evening routine may give your heart a measurable boost. In a new study, adults who stopped eating and dimmed the lights three hours before bed and extended their overnight fast by about two hours saw improvements in blood pressure, heart rate, and blood-sugar control — without cutting calories.Researchers at Northwestern Medicine explored whether timing an overnight fast to match a person's natural sleep wake cycle could improve heart and metabolic health. The circadian rh

Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s single‑dose chikungunya vaccine, IXCHIQ ® , the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine. The updated Prescribing Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years

SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101 , its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology, and CNS drug delivery. Background on OT-101 OT-101 (TGF-β antisense inhibitor) is a clinical-stage therapeutic with prior oncology trials including glioblastoma and pancreatic cancers. The Company is advancing OT-101 as a CNS-capable therapeutic plat

Scientists have created the most detailed maps yet of how genes control one another inside the brains of people with Alzheimer’s disease. Using a powerful new AI-based system called SIGNET, the team uncovered cause-and-effect relationships between genes across six major brain cell types, revealing which genes are truly driving harmful changes. The most dramatic disruptions were found in excitatory neurons, where thousands of genetic interactions appear to be extensively rewired as the disease pr

The Trade-off Between Physiological Authenticity and Experimental Convenience: Navigating the Cellular Foundation of Life Science Research WUHAN, HUBEI PROVINCE, CHINA, February 15, 2026 / EINPresswire.com / -- In the complex landscape of life science research, selecting the right cellular model is a foundational decision that dictates the trajectory of scientific discovery. This article provides a comprehensive comparison between primary cells—the "original blueprints" harvested directly from l

Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025

GA, UNITED STATES, February 14, 2026 / EINPresswire.com / -- Diabetic retinopathy remains a leading cause of preventable vision loss, yet predicting which patients will experience disease progression remains challenging. This study demonstrates that subtle changes in retinal blood vessel geometry triggered by simple postural shifts—from sitting to lying down—carry important prognostic information. By analyzing how retinal vessels respond dynamically to altered blood flow demands, the research id

Machine learning models showed roughly 40% improvement in diagnostic accuracy compared to standard oral food challenges, skin prick tests, and allergen-specific IgE measurements MILWAUKEE, Feb. 14, 2026 /PRNewswire/ -- Both machine learning and deep learning AI models show significant improvements over existing clinical criteria of food allergy diagnostics, according to new research being presented at the 2026 AAAAI Annual Meeting. "The current standard of care for food allergy diagnosis relies

Welcome back to Endpoints Weekly! A programming note: We won’t be sending our usual newsletters on Monday, Feb. 16. Our team will be off for Presidents’ Day. Our reporters closely followed several big updates this week, including Moderna’s response after it received a refusal-to-file letter over its flu vaccine application and Paul Hudson’s exit from Sanofi. Senior editor Max Gelman also dug into what makes clinical trials so costly. And our team reported on readouts for AstraZeneca’s obesity pi